| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$144 |
Appendix 4E - Preliminary Final Report
|
30 Aug 2024 9:18AM |
$0.415 |
$0.320 |
fallen by
22.89%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- Group reported a comprehensive loss of $36.2m for FY2024.
- FY2024 operating revenue was $3.8m, up 422% from FY2023.
- Significant increase in SaaS revenue to $3.0m.
- Acquisition of Imbio Inc. for AU$60.24 million.
- Imbio post-acquisition revenue was $2.7m with a net operating loss of $1.3m.
- Total reported income of $14.8m for FY2024.
- 4DMedical’s operating expenses reduced by 3.4% due to decreased R&D and clinical trial expenditure.
- The company raised $35 million through new share issuance.
- No dividends have been declared or paid.
- MRFF Grant and CTCM Grant received for developing the XV Scanner.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nexion Group Ltd (NNG) ORDINARY FULLY PAID |
Information Technology |
$4 |
NNG ASX Appendix 4G
|
30 Aug 2024 9:17AM |
$0.020 |
$0.020 |
fallen by
0%
|
|
| IRIS Metals Limited (IR1) ORDINARY FULLY PAID |
Materials |
$28 |
AGM Investor Presentation
|
30 Aug 2024 9:17AM |
$0.180 |
$0.160 |
fallen by
11.11%
|
|
| Joyce Corporation Limited (JYC) ORDINARY FULLY PAID |
Consumer Discretionary |
$137 |
Dividend/Distribution - JYC
|
30 Aug 2024 9:17AM |
$4.100 |
$4.650 |
risen by
13.41%
|
|
| Orange Minerals NL (OMX) ORDINARY FULLY PAID |
Materials |
$5 |
Resignation of Managing Director
|
30 Aug 2024 9:16AM |
$0.025 |
$0.041 |
risen by
64%
|
|
OMX - Price-sensitive ASX Announcement
Full Release
Key Points
- David Greenwood, Managing Director, resigns effective 30 November 2024.
- Greenwood will continue to serve during the notice period or until a replacement is found.
- Board expresses gratitude for Greenwood's service.
- Search for a new executive to commence.
- Greenwood has been Managing Director since December 2021.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$86 |
Appendix 4G
|
30 Aug 2024 9:16AM |
$0.042 |
$0.027 |
fallen by
35.71%
|
|
| Talius Group Limited (TAL) ORDINARY FULLY PAID |
Information Technology |
$23 |
Talius Group Sales Update 2H24
|
30 Aug 2024 9:16AM |
$0.007 |
$0.008 |
risen by
14.29%
|
|
| Duxton Farms Ltd (DBF) ORDINARY FULLY PAID |
Consumer Staple |
$55 |
Update - Notification of buy-back - DBF
|
30 Aug 2024 9:16AM |
$1.595 |
$1.335 |
fallen by
16.30%
|
|
| Greenwing Resources Ltd (GW1) ORDINARY FULLY PAID |
Materials |
$6 |
Becoming a substantial holder
|
30 Aug 2024 9:16AM |
$0.053 |
$0.026 |
fallen by
50.94%
|
|
| Australian Unity Office Property Fund (AOF) ORDINARY UNITS FULLY PAID |
Real Estate |
$79 |
30 June 2024 Financial Results and Investor Update
|
30 Aug 2024 9:16AM |
$1.240 |
$0.480 |
fallen by
61.29%
|
|
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$14 |
Annual Report
|
30 Aug 2024 9:16AM |
$0.021 |
$0.009 |
fallen by
59.52%
|
|
| Firstwave Cloud Technology Limited (FCT) ORDINARY FULLY PAID |
Information Technology |
$31 |
FirstWave Cuts Losses as Foundation for FY25
|
30 Aug 2024 9:16AM |
$0.019 |
$0.018 |
fallen by
5.26%
|
|
FCT - Price-sensitive ASX Announcement
Full Release
Key Points
- FirstWave targets to be cashflow positive in FY25
- Consolidated entity loss reduced to $3.08 million from $5.86 million
- Normalized cash burn reduced to $280K per month
- Operational improvements and synergies lowered operating costs by $4.17 million
- Total revenue for the year was $11.28 million, down 9.7%
- Acquired 100% of Saisei Networks Inc. assets
- Raised $2.5 million via convertible notes from Formue Nord A/S
- Extended Professional Services Agreement with Telstra and NMIS agreement with NASA
- Added Telmex as a reseller of NMIS platform
- Appointment of Daniel Friel as a Non-Executive Director
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pioneer Credit Limited (PNC) ORDINARY FULLY PAID |
Financials |
$73 |
Board of Director Changes - App 3Z and 3X
|
30 Aug 2024 9:16AM |
$0.540 |
$0.455 |
fallen by
15.74%
|
|
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$21 |
1H24 - Half-Year Report
|
30 Aug 2024 9:15AM |
$0.090 |
$0.140 |
risen by
55.56%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- Recorded a net profit after tax of $28k, recovering from a $1.6m loss in 1H23
- Revenue increased by 64% to $16.9m
- EBITDA improved to $2.3m from $0.2m in 1H23
- Ikon Institute enrolments increased by 85%
- ALG enrolments grew by 24%
- Significant growth in higher education course enrolments
- Launch of two new accredited Masters Degrees scheduled for 1H25
- Continued focus on expanding course portfolio and leveraging online delivery
- Cash at bank increased to $8.0m from $3.1m at the end of 2023
- Future challenges anticipated from new regulatory caps on international student enrolments
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$6,517 |
Appendix 4G for FY24
|
30 Aug 2024 9:15AM |
$4.890 |
$5.230 |
risen by
6.95%
|
|
| Talius Group Limited (TAL) ORDINARY FULLY PAID |
Information Technology |
$23 |
Talius Group 2024 Half Year Results Investor Presentation
|
30 Aug 2024 9:15AM |
$0.007 |
$0.008 |
risen by
14.29%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$86 |
Corporate Governance Statement
|
30 Aug 2024 9:15AM |
$0.042 |
$0.027 |
fallen by
35.71%
|
|
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$6,517 |
Results Announcement for FY24
|
30 Aug 2024 9:15AM |
$4.890 |
$5.230 |
risen by
6.95%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong operating cash flows of $686.53 million at a cash conversion rate of 100.4%
- Net assets increased to $4.54 billion
- Total system sales revenue reached $8.86 billion
- Reported profit before tax (PBT) was $541.69 million, a 30.2% decrease from FY23
- Emerging AI-PC market expected to drive future sales growth
- Significant reduction in net debt to equity ratio to 14.49%
- Maintained a solid asset base of nearly $8 billion
- Emphasis on omni-channel strategy to leverage brand and geographical reach
- Home Appliances, Mobile & Computer Technology categories poised for growth in FY25 and beyond
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$86 |
ACW FY2024 results, advancing into late-stage trials
|
30 Aug 2024 9:14AM |
$0.042 |
$0.027 |
fallen by
35.71%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical (ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases.
- Their lead compound, Xanamem, targets the inhibition of cortisol production in the brain, potentially benefiting conditions like Alzheimer's Disease and Depression.
- The XanaCIDD Phase 2a trial showed promising results on depression and cognitive function.
- The XanaMIA Phase 2b Alzheimer's disease trial aims to assess Xanamem's effects on cognition and disease progression.
- The company received a UK Innovation Passport for Xanamem in Alzheimer's treatment.
- Statutory financial results for FY2024 showed a net loss of $13,044,282, with significant investments in R&D.
- Key highlights include the start of new clinical sites in Australia and the US for the XanaMIA trial.
- Future plans include longer treatment periods for depression trials and potential Phase 2b trials starting in mid-2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cape Range Ltd (CAG) ORDINARY FULLY PAID |
Information Technology |
$9 |
Appendix 4D and 30 June 2024 Half Year Financial Statements
|
30 Aug 2024 9:14AM |
$0.190 |
$0.090 |
fallen by
52.63%
|
|
CAG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities increased by 14% to A$294,000.
- Loss from ordinary activities after tax reduced by 30% to A$211,000.
- No dividends were declared for the half year ended 30 June 2024.
- Net tangible assets per ordinary share decreased to 1.6 cents from 2.0 cents in the previous period.
- The company did not gain or lose control over any entities during the reporting period.
- No associates or joint venture entities are reported.
- An impairment charge of $86,823 was recorded.
- Cash and cash equivalents decreased to A$1,708,361 from A$1,902,149 at the beginning of the period.
- No significant subsequent events affecting the company's operations were reported.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Artrya Limited (AYA) ORDINARY FULLY PAID |
Health Care |
$71 |
Appendix 4E and Annual Financial Statements June 2024
|
30 Aug 2024 9:14AM |
$0.320 |
$0.630 |
risen by
96.88%
|
|
AYA - Price-sensitive ASX Announcement
Full Release
Key Points
- Artrya Limited focused on developing AI platform Salix for coronary artery disease.
- Loss for the year ended June 30, 2024, increased by 25.7% to $14 million.
- No dividends were paid, recommended, or declared during the financial period.
- Cash balance at the end of the financial year was $7.1 million, down from $20.1 million the previous year.
- FDA 510(k) clearance for Salix Coronary Anatomy product expected in first half of FY25.
- First commercial agreement in Australia with The Cardiac Centre NSW, revenue expected in Q1 FY25.
- Strategic partnership agreements in the US with Northeast Georgia Health Ventures, Tanner Health System, and Cone Health.
- Operating cash outflows for the year amounted to $15.41 million.
- Total net assets decreased from $30.6 million to $16.8 million.
- Investment in Salix platform to improve detection and treatment of coronary artery disease.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$6,517 |
Presentation of Results for FY24
|
30 Aug 2024 9:14AM |
$4.890 |
$5.230 |
risen by
6.95%
|
|
HVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net assets increased by $70.44 million (+1.6%) from June 2023.
- Substantial growth of 41.9% in net assets since June 2019.
- Operating cash flows rose by $6.27 million to $686.53 million.
- Reported profit before tax (PBT) declined by $234.39 million (-30.2%) from FY23.
- Total revenue decreased by $165.21 million (-3.9%) from FY23.
- Decrease in franchise fees due to a reduction in aggregated franchisee sales revenue.
- Increase in company-operated sales revenue by $27.29 million.
- Cost of sales increased by $46.91 million (+2.5%) due to new overseas stores.
- Operating expenses rose by $25.01 million (+1.5%) due to inflation and new store openings.
- Effective tax rate was higher at 33.98% for FY24 due to a deferred tax expense in New Zealand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nickelx Limited (NKL) ORDINARY FULLY PAID |
Materials |
- |
Proposed issue of securities - NKL
|
30 Aug 2024 9:14AM |
$0.020 |
$0.029 |
risen by
45%
|
|
| Harvey Norman Holdings Ltd (HVN) ORDINARY FULLY PAID |
Consumer Discretionary |
$6,517 |
Dividend/Distribution - HVN
|
30 Aug 2024 9:14AM |
$4.890 |
$5.230 |
risen by
6.95%
|
|
| US Masters Residential Property Fund (URF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$266 |
Update - Notification of buy-back - URF
|
30 Aug 2024 9:14AM |
$0.310 |
$0.385 |
risen by
24.19%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
